



## The Determination of Pt for Cancer Studies

M. Metzger  
Hôpital P. Brousse  
Villejuif, France

Nathalie Le Corre, Agnès Cosnier  
Jobin Yvon S.A.S., Horiba Group  
Longjumeau, France

**Keywords:** medical

### 1 Introduction

Platinum complexes, such as cisplatin, carboplatin, and oxaliplatin, have been used since the early 1970s to treat various solid tumors (testicles, ovaries, head, neck and, recently, colon). It was found that platinum is fixed in a covalent way to the DNA, forming various types of adducts. The tumor treatment properties of platinum complexes are directly connected to the fixation of platinum on DNA.

The influence of platinum on the reparation of DNA is dependent on the time the injection was done in an organism. This is the same for the toxicity that platinum complexes can reveal on other organs, which is determined by analyzing solutions coming from extraction of target organs over time. The quantity of solutions is around 1 milliliter.

Phosphorus and sulfur were also determined. Phosphorus allows direct determination of the proportion of platinum to nucleotide, knowing that there is one atom of phosphorus per nucleotide of DNA.

### 2 Principle

#### 2.1 Technique used

The elemental analysis of solutions was undertaken by Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES). The sample is nebulized then transferred to an argon plasma. It is decomposed, atomized and ionized whereby the atoms and ions are excited. We measure the intensity of the light emitted when the atoms or ions return to lower levels of energy. Each element emits light at characteristic wavelengths and these lines can be used for quantitative analysis after a calibration.

#### 2.2 Wavelength choice

The choice of the wavelength in a given matrix can be made using the "profile" function, or by using Win-IMAGE, which is rapid semi-quantitative analysis mode using multiple wavelengths. The principle is the same in either case: record the scans of analytes at low concentration, and of the matrix. By superimposing the spectra, we see possible interferences.

#### 2.3 Limits of detection estimation

The limits of detection are calculated using the following formula:

$$\text{LOD} = k \times \text{BEC} \times \text{RSD}_0$$

With:

LOD = limits of detection,

$k = 3$  for the normal 3-sigma values,

BEC = Background equivalent concentration,

$\text{RSD}_0$  = relative standard deviation of the blank.

To calculate the LOD, a calibration curve is constructed using two points, 0 ppm and 5 ppm, or some concentration where the calibration is linear; this gives the BEC. The  $\text{RSD}_0$  is evaluated by running the blank ten times.

### 3 Sample preparation

Samples were obtained by extraction from the spleen, liver, kidney, intestine and brain of mice. For the kidney, the samples were diluted by a factor of 6 (0.5 mL in 3 mL). For the brain and intestine a dilution of 2X was made.



## 4 Instrument specification

The work was done on a JY ULTIMA. The specifications of this instrument are listed below in Table 1 and 2.

**Table 1: Specification of spectrometer**

Parameters	Specifications
Mounting	Czerny Turner
Focal length	1 m
Nitrogen purge	Yes
Variable resolution	Yes
Grating number of grooves	2400 gr/mm
1 <sup>st</sup> order resolution	0.010 nm
2 <sup>nd</sup> order resolution	0.005 nm
Order	2 <sup>nd</sup> order

**Table 2: Specification of RF Generator**

Parameters	Specifications
Type of generator	Solid state
Observation	Radial
Frequency	40.68 MHz
Control of gas flowrate	by computer
Control of pump flow	by computer

## 5 Operating conditions

The operating conditions are listed in Table 3 below.

**Table 3: Operating conditions**

Parameter	Condition
RF Generator power	1200 W
Plasma gas flowrate	16 L/min
Auxiliary gas flowrate	0 L/min
Sheath gas flowrate	0.2 L/min
Nebulizer flowrate	0.16 bars
Sample uptake	1 mL/min
Type of nebulizer	Ultrasonic
Injector tube diameter	3.0 mm

## 6 Wavelength selection and analytical conditions

The line with the highest sensitivity was used for analysis of all analytes, as there were no problems with interferences. The analysis conditions were the same for all elements.

**Table 4: Analytical conditions**

Element	Slits $\mu\text{m}$	Analysis Mode	Integration Time (sec)
P	20 x 15	Gaussian	0.2
Pt	20 x 15	Three points on peak	3
S	20 x 15	Gaussian	0.2

## 7 Discussion

### 7.1 Limit of Detection

The limit of detection for platinum of 0.1 mg/L was calculated using the formula in paragraph 2.3.

### 7.2 Results

The samples were measured using an autosampler. Concentrations are in mg/L for S and P and in  $\mu\text{g/L}$  for Pt.



**Table 5: Intestine sample results**

	J30-	J1-	J2-	J4-	J8-	J12-	J24-
S	10.88 ± 1.27	0.66 ± 0.05	10.46 ± 0.41	11.52 ± 1.14	9.59 ± 1.50	6.66 ± 1.46	6.26 ± 1.05
Pt	74.83 ± 9.20	5.73 ± 0.76	81.59 ± 1.30	70.09 ± 2.94	29.21 ± 1.84	83.16 ± 5.00	30.78 ± 2.86
P	530.16 ± 47.71	47.86 ± 2.58	368.37 ± 25.42	260.88 ± 14.87	317.52 ± 63.25	477.81 ± 30.10	264.97 ± 23.05

  

	J30+	J1+	J4+	J8+	J12+	J24+	J48+
S	5.38 ± 0.15	4.83 ± 0.23	6.37 ± 0.52	6.11 ± 0.33	6.54 ± 0.27	0.75 ± 0.08	3.47 ± 0.21
Pt	59.67 ± 2.33	45.37 ± 5.17	40.57 ± 2.07	83.63 ± 6.02	67.76 ± 1.32	8.13 ± 0.56	57.48 ± 3.10
P	260.98 ± 12.53	284.39 ± 10.24	408.10 ± 15.92	312.57 ± 20.63	367.46 ± 26.46	50.91 ± 1.30	189.82 ± 9.57

**Table 6: Brain sample results**

	C30-	C1-	C2-	C4-	C8-	C12-	C24-	C48-
S	5.57	3.41	4.79	4.63	4.87	3.97	3.94	3.98
	± 0.24	± 0.42	± 0.15	± 0.60	± 0.69	± 0.93	± 0.48	± 0.51
Pt	0.276	0.471	0.564	0.561	0.187	0.379	0.212	0.202
	± 0.288	± 0.183	± 0.072	± 0.075	± 0.348	± 0.420	± 0.228	± 0.363
P	77.23	62.01	86.40	90.56	87.71	72.86	76.33	79.80
	± 4.68	± 2.76	± 6.54	± 2.52	± 6.75	± 22.06	± 5.58	± 11.64

  

	C30+	C1+	C2+	C4+	C8+	C12+	C24+	C48+
S	3.79	3.65	4.13	4.06	3.45	2.66	2.62	3.23
	± 0.28	± 7.4	± 0.72	± 0.45	± 0.84	± 1.29	± 0.06	± 0.42
Pt	0.492	0.511	0.416	0.314	0.344	0.323	0.225	0.547
	± 0.177	± 0.417	± 0.507	± 0.207	± 0.495	± 0.279	± 0.204	± 0.306
P	83.69	93.04	83.48	89.16	81.29	81.40	56.21	81.44
	± 3.9	± 10.08	± 1.67	± 9.63	± 8.88	± 5.61	± 3.6	± 19.17

**Table 7: Liver sample results**

	Pt (µg/L)	RSD (%)	P (mg/L)	RSD (%)	S (mg/L)	RSD (%)
Oa	7.8	18	341.4	3	9.12	5.6
Ob	5.4	11	318.7	2.9	10.8	5.5
Oc	9	12	345	5.7	13.9	10
8a	6.6	8.9	401.4	5.5	10.2	5.2
8b	5.4	7.8	326.4	4	7.5	3.3
8c	4.2	12	325.8	3.5	7.8	1
16a	7.2	2.2	246.6	4.8	12	1.9
16b	6.6	18	247.8	1.5	7.8	5.9
16c	9	13	237	3.3	7.8	5.5
Oa-	166.8	3.2	343.2	2.5	18	1.7
Ob-	208.8	1.9	348.6	8.5	15.6	5.2
Oc-	256.8	1.7	367.8	3.1	12	3.5
8a-	153	3.3	278.4	0.8	7.8	1.2
8b-	190.8	1.4	346.2	3.1	8.4	1.9
8c-	100.8	1.7	299.4	5.8	7.2	4.5
16a-	172.8	3.4	313.2	4.4	9.6	4.6
16b-	191.4	2	273	3.1	10.2	3
16c-	121.8	5.7	288.6	7	12.6	0.69
Oa+	134.4	1.4	282.6	9.8	10.8	10
Ob+	157.8	1.4	278.4	4.5	8.4	2.4
Oc+	118.2	3.4	285	6.1	9	6.1
8a+	181.8	2.2	361.8	6	8.4	6.1
8b+	111	1.7	243	4.2	5.4	4.2
8c+	180	0.37	316.8	4.9	7.4	1.2
16a+	130.2	0.31	287.4	5.1	6.4	3
16b+	104.4	1.9	250.8	7	4.8	5.6
16c+	91.2	4.6	269.4	2	4.8	4.1



Table 8: Kidney sample results

	Pt ( $\mu\text{g/L}$ )	RSD (%)	P (mg/L)	RSD (%)	S (mg/L)	RSD (%)
0a	6.7	10	56.9	3.7	1.6	3.2
0b	11.7	10	48.6	1.9	1.5	7.6
0c	13.4	5.9	47.4	8.1	1.2	12
8c	9.1	6.7	47.4	5	1.2	5.4
16c	5.4	19	7.62	2		
0b-	81.7	0.8	38.2	10	4	8
0c-	43.5	6.4	53.7	6.9	1.3	2.2
8a-	15.5	4.7	14.4	2.2	0.7	5.5
8b-	11.5	7.4	6.7	15		
8c-	32.3	4.1	53.4	1.7	1.3	4.3
16b-	10.4	8.8	7	8		
16c-	27.2	1.7	65.5	4.6	1.7	6
0a+	38.8	0.37	66.3	5.2	1.7	15
0b+					2.6	6
0c+	22.7	7.9	44.97	4	1.62	3.3
8b+	39.7	2				
8c+	10.9	9.7	0.93	8		
16a+	36.1	4.1	67.8	5.8	1.9	6
16b+	10.8	9.2	2.6	20		
16c+	28.5	2.5	45.9	5	1.3	7

## 8 Summary

The results in this Application Note demonstrate that it is possible to detect very low levels of an analyte using the ultrasonic nebulizer, even with a very small amount of sample (one to two millimeters). Applications of ICP-OES in the medical field are not very well developed, but the work done here shows the feasibility in cancer treatments.



**In the USA:**  
Jobin Yvon Inc.  
3880 Park Avenue  
Edison, NJ 08820  
Tel: 1-732-494-8660  
Fax: 1-732-494-8796  
E-mail:  
emission@jyhoriba.com

**In France:**  
Jobin Yvon S.A.S.  
16-18, rue du Canal  
91165 Longjumeau Cedex  
Tel: (33) 1/64 54 13 00  
Fax: (33) 1/69 09 90 88

**In Japan:**  
Horiba Ltd.  
2 Miyano Higashi, Kisshoin  
Minami-ku, Kyoto 601-8510  
TEL: (81) 75 313 8121  
FAX: (81) 75 321 5725  
www.horiba.com

**Germany:** (49) 89/46 23 17-0  
**Italy:** (39) 2/57 60 56 90  
**U.K.:** (44) 20/82 04 81 42

**China:** (86) 10/6836 6542  
**Spain:** (34) 91/724 16 57  
**Other Countries:** Contact JY S.A.S.

1-877-JYHORIBA

www.jyhoriba.com



**HORIBA GROUP**

EMISSION • FLUORESCENCE • FORENSICS • GRATINGS & OEM • RAMAN • OPTICAL SPECTROSCOPY • THIN FILM